2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Treatment Considerations, Supportive Care, Biological Therapies, Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Quality Improvement, Systems-Based Hematology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Autoimmune Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

3082 Preemptive obinutuzumab for ADAMTS13 relapse in rituximab-intolerant immune TTP

Leeanne Mako, CNP, MSN, MPH, Camila Masias, MD, MPH2, Senthil Sukumar, MD,MSc3, Spero R Cataland, MD4
1 Ohio State University, Columbus, United States
2 Baptist Health, Miami Beach, Florida, United States
3 Baylor College of Medicine, Houston, Texas, United States
4 Ohio State University, Columbus, Ohio, United States

Background: Patients with immune thrombotic thrombocytopenic purpura (iTTP) typically receive preemptive treatment for ADAMTS13 relapse with rituximab (RTX) to mitigate the risk of clinical relapse. RTX (4 weekly infusions, 375 mg/m2) infusions are the current standard of care. A subset of patients, however, are unable to tolerate RTX due to allergic reaction, serum sickness, or preference. Recent data may suggest that Black patients have attenuated response to RTX compared with White patients. Obinutuzumab (OBI), a fully humanized anti-CD20 monoclonal antibody, has been reported to be safe and effective preemptive therapy in iTTP patients with an ADAMTS13 relapse.

Methods: We retrospectively reviewed patients with iTTP at time of ADAMTS13 relapse (≤20%) who had received OBI due to RTX intolerance. A cycle of OBI was 1 g every 7 days for a total of 4 doses, with the first dose split over 24 hours with an initial 100 mg desensitization dose. Our cohort included 7 patients that were intolerant of rituximab (allergic reactions or serum sickness) and 1 patient with a religious objection to treatment with a murine chimeric monoclonal antibody (RTX) that were found to be in biochemical relapse (n=5), or treated in recovery from a recent acute iTTP episode (n=2) with an ADAMTS13 <20%. Patients in the OSU TMA Registry were consented and enrolled and followed prospectively in the clinic every 3 to 6 months for clinical follow up and measurement of ADAMTS13 activity in addition to other biomarkers of disease.

Results: A total of 8 patients received a total of 10 obinutuzumab cycles from October 2022 to December 2025 after documented rituximab intolerance or religious objection. There were 6 females and 2 males, with Black patients (n=3), White (n=4), and Asian patients (n=1) represented in the cohort. Five of the 7 RTX intolerant patients developed a severe allergy, characterized by hives, rigors, and angioedema. One of the allergic patients was also refractory to treatment (rituximab, cyclosporine, and splenectomy) with persistently low ADAMTS13 activity over the preceding 67 months. Two subjects developed serum sickness, and the remaining patient had religious objections to rituximab. The median number of previous acute iTTP episodes in this cohort was 3 (range, 1 to 5), and the median number of rituximab cycles received was 2 (range, 1 to 6) for the subjects in this cohort.  

All patients achieved partial or complete ADAMTS13 activity (≥20%) response after preemptive OBI treatment. Obinutuzumab was well tolerated, with no evidence of allergy or serum sickness in the 10 cycles among the 8 patients. Three patients experienced infusion-related reactions during the first dose but tolerated remaining cycle doses without reaction. Reported symptoms included: headache, arthralgias, and dyspnea, which resolved after symptomatic treatment per local infusion protocol. Two patients developed an ADAMTS13 relapse 12 and 18 months after their first courses of obinutuzumab and were retreated with a good response. The other 6 patients receiving their first obinutuzumab course had a continuous ADAMTS13 partial or complete remission after a median of 18 months (range 13-29) of follow-up.

Conclusions: Overall, obinutuzumab was well tolerated among the 8 patients with either allergic reactions or serum sickness after previous treatment with rituximab. All OBI-treated patients achieved a partial or complete ADAMTS13 activity remission, supporting obinutuzumab as an appropriate alternative among patients with iTTP who are intolerant of or refractory to rituximab. Consistent with prior reports, OBI would be a reasonable option in patients that have not responded to rituximab with an improved ADAMTS13 activity. A prospective study is needed to better define the efficacy and safety of obinutuzumab in patients with iTTP who are intolerant or refractory to rituximab.

Leeanne Mako, CNP, MSN, MPH: No relevant conflicts of interest to declare.